讨论
牛唐2021-04-13 21:53
$再鼎医药(ZLAB)$ 选药眼光真毒,$Five Prime(FPRX)$ 被收购,$Novocure(NVCR)$ 数据不错查看全文
简介:Five Prime Therapeutics, Inc.于2001年12月根据特拉华州法律注册成立,是一家临床阶段的生物技术公司,致力于发现和开发新的蛋白质疗法。蛋白质治疗剂是阻断疾病过程中细胞外蛋白质或蛋白质片段产生抗体或药物,包括癌症和炎症性疾病。该公司没有批准用于商业销售的产品,到目前为止并没从产品销售中获取任何收入。
今开: | 昨收:38 |
最高: | 最低: |
涨停价: | 跌停价: |
总市值:1769737102 |
牛唐2021-04-13 21:53
$再鼎医药(ZLAB)$ 选药眼光真毒,$Five Prime(FPRX)$ 被收购,$Novocure(NVCR)$ 数据不错查看全文
7X24快讯2021-03-05 14:44
【安进19亿美元收购Five Prime Therapeutics】3月4日,安进(AMGN.O)宣布与Five Prime Therapeutics(FPRX.O)达成最终协议,将以38美元/股的价格全现金收购后者股票,对应股权总金额大约19亿美元。安进通过此次收购补强了自己的肿瘤创新药管线,包括获得了first in class的FGFR2b单抗bemarituzumab,...查看全文
牛唐2021-03-05 14:16
医药板块观察(2021.03.04)
1、$Five Prime(FPRX)$\$Pandion Therapeutics(PAND)相继被并购,可否燃起医药板块的热情?
2、$Talis Biomedical(TLIS)$ 新股破发,是否有配置价值?
$快手-W(01024)$查看全文
小小糖果2021-03-05 03:31
$Five Prime(FPRX)$ 今天唯一的安慰。查看全文
lisaff2021-03-05 01:15
$Five Prime(FPRX)$ 这么平的走势,怎么做到的呢查看全文
chuminhua2021-03-04 23:29
3月4日,安进(Amgen)宣布将以19亿美元收购Five Prime。Five Prime的核心产品为FGFR2b抗体bemarituzumab等。再鼎医药于2017年以500万美元预付款+3900万美元里程碑金额引进Bemarituzumab的大中华区权益。$安进(AMGN)$ $Five Prime(FPRX)$查看全文
产业链观察2021-03-04 22:35
药闻| 2021年3月4日,- $安进(AMGN)$ 和$Five Prime(FPRX)$ (一家临床阶段的生物技术公司,专注于开发免疫肿瘤以及针对性癌症疗法),今天宣布了一项协议,安进公司将以每股38.00美元的现金价格收购Five Prime Therapeutics ,相当于约19亿美元的股权价值。
此次收购将Five Prime的创新产品线添...查看全文
Replix锐璞美股2021-03-04 22:03
$Five Prime(FPRX)$ 被收购!
Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime ...查看全文
牛唐2020-12-08 22:00
$居里(CRIS)$ 继$Five Prime(FPRX)$ 之后,第二个爆发的BVF概念股,下一个是谁?$蔚来(NIO)$查看全文
chuminhua2020-11-12 22:14
Five Prime Therapeutics日前宣布,其“first-in-class”靶向FGFR2b的单克隆抗体疗法bemarituzumab(FPA144),与化疗联用,在一线治疗晚期胃癌或胃食管连接部(GEJ)癌患者的2期临床试验中获得积极结果。这些患者的肿瘤为FGFR2b阳性,HER2阴性。新闻稿指出,这是首个表明针对FGFR2b的靶向治疗可能...查看全文
$Five Prime(FPRX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-119360 Act: 33 Size: 28 KB 网页链接
$Five Prime(FPRX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-119362 Act: 33 Size: 28 KB 网页链接
$Five Prime(FPRX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-119370 Act: 33 Size: 28 KB 网页链接
$Five Prime(FPRX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-119330 Act: 33 Size: 28 KB 网页链接
$Five Prime(FPRX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-119341 Act: 33 Size: 28 KB 网页链接
$Five Prime(FPRX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-119342 Act: 33 Size: 28 KB 网页链接
$Five Prime(FPRX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-119352 Act: 33 Size: 28 KB 网页链接
$Five Prime(FPRX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-119353 Act: 33 Size: 28 KB 网页链接
$Five Prime(FPRX)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-21-119305 Act: 33 Size: 19 KB 网页链接
$Five Prime(FPRX)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-21-000482 Act: 34 Size: 3 KB 网页链接